Lung cancer is one of the most common malignant neoplasms. As a result of the disease's
progression, patients may develop metastases to the central nervous system. The prognosis …

Brain metastases (BrMs) are associated with significant morbidity and are found in up to
50% of patients with advanced non-small cell lung cancer (NSCLC). Most of the literature …

Three generations of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …

Background Within the field of oncotherapy, research interest regarding immunotherapy has
risen to the point that it is now seen as a key application. However, inherent disadvantages …

Non-small cell lung cancer (NSCLC) is frequently complicated by central nervous system
(CNS) metastases affecting patients' life expectancy and quality. At the present clinical trials …

Background A growing number of regimens have been approved as first-line treatments for
patients with advanced epidermal growth factor receptor (EGFR) mutated non-small cell …

Purpose It is unclear whether local therapy (LT) or epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) should take precedence for patients with EGFR-mutant non …

Introduction: The purpose of this article is to report our institution's 10-year experience on
palliative radiotherapy for the treatment of leptomeningeal carcinomatosis (LC), assessing …

Opinion statement Systemic therapy for brain metastases (BM) is quickly moving from
conventional cytotoxic chemotherapy toward targeted therapies, that allow a disruption of …

Background It remains uncertain whether first-line treatment with upfront brain radiotherapy
(RT) in combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR …